Shirakawa T - Search Results

1

Gene therapy for bladder cancer using adenoviral vector.

Wada Y, Gotoh A, Shirakawa T, Hamada K, Kamidono S. Wada Y, et al. Among authors: shirakawa t. Mol Urol. 2001 Summer;5(2):47-52. doi: 10.1089/109153601300177547. Mol Urol. 2001. PMID: 11690547

2

p53 adenoviral vector (Ad-CMV-p53) induced prostatic growth inhibition of primary cultures of human prostate and an experimental rat model.

Shirakawa T, Gotoh A, Gardner TA, Kao C, Zhang ZJ, Matsubara S, Wada Y, Hinata N, Fujisawa M, Hanioka K, Matsuo M, Kamidono S. Shirakawa T, et al. J Gene Med. 2000 Nov-Dec;2(6):426-32. doi: 10.1002/1521-2254(200011/12)2:6<426::AID-JGM140>3.0.CO;2-2. J Gene Med. 2000. PMID: 11199263

3

Adenovirus-mediated p53 gene transfer to rat testis impairs spermatogenesis.

Fujisawa M, Shirakawa T, Fujioka H, Gotoh A, Okada H, Arakawa S, Kamidono S. Fujisawa M, et al. Among authors: shirakawa t. Arch Androl. 2001 May-Jun;46(3):223-31. doi: 10.1080/01485010151096568. Arch Androl. 2001. PMID: 11339649

4

Drug-resistant human bladder-cancer cells are more sensitive to adenovirus-mediated wild-type p53 gene therapy compared to drug-sensitive cells.

Shirakawa T, Sasaki R, Gardner TA, Kao C, Zhang ZJ, Sugimura K, Matsuo M, Kamidono S, Gotoh A. Shirakawa T, et al. Int J Cancer. 2001 Oct 15;94(2):282-9. doi: 10.1002/ijc.1453. Int J Cancer. 2001. PMID: 11668510

5

Additional gene therapy with Ad5CMV-p53 enhanced the efficacy of radiotherapy in human prostate cancer cells.

Sasaki R, Shirakawa T, Zhang ZJ, Tamekane A, Matsumoto A, Sugimura K, Matsuo M, Kamidono S, Gotoh A. Sasaki R, et al. Among authors: shirakawa t. Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1336-45. doi: 10.1016/s0360-3016(01)01803-x. Int J Radiat Oncol Biol Phys. 2001. PMID: 11728695

6

Tissue-specific promoters in gene therapy for the treatment of prostate cancer.

Shirakawa T, Gotoh A, Wada Y, Kamidono S, Ko SC, Kao C, Gardner TA, Chung LW. Shirakawa T, et al. Mol Urol. 2000 Summer;4(2):73-82. doi: 10.1089/10915360050138620. Mol Urol. 2000. PMID: 12006246 Review.

7

The growth inhibitory effect of p21 adenovirus on androgen-dependent and -independent human prostate cancer cells.

Gotoh A, Shirakawa T, Wada Y, Fujisawa M, Okada H, Kamidono S, Hamada K. Gotoh A, et al. Among authors: shirakawa t. BJU Int. 2003 Aug;92(3):314-8. doi: 10.1046/j.1464-410x.2003.04318.x. BJU Int. 2003. PMID: 12887490

8

Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer.

Gotoh A, Ko SC, Shirakawa T, Cheon J, Kao C, Miyamoto T, Gardner TA, Ho LJ, Cleutjens CB, Trapman J, Graham FL, Chung LW. Gotoh A, et al. Among authors: shirakawa t. J Urol. 1998 Jul;160(1):220-9. J Urol. 1998. PMID: 9628654

9

Cytotoxicity of adenoviral-mediated cytosine deaminase plus 5-fluorocytosine gene therapy is superior to thymidine kinase plus acyclovir in a human renal cell carcinoma model.

Shirakawa T, Gardner TA, Ko SC, Bander N, Woo S, Gotoh A, Kamidono S, Chung LW, Kao C. Shirakawa T, et al. J Urol. 1999 Sep;162(3 Pt 1):949-54. doi: 10.1097/00005392-199909010-00096. J Urol. 1999. PMID: 10458414

10

[Prospects for molecular research in urological oncology: gene therapy].

Gotoh A, Shirakawa T, Wada Y, Hinata N, Hara I, Fujisawa M, Okada H, Arakawa S, Kamidono S. Gotoh A, et al. Among authors: shirakawa t. Hinyokika Kiyo. 2001 Nov;47(11):829-32. Hinyokika Kiyo. 2001. PMID: 11771180 Free article. Japanese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

710 results

Search Page

Filters